GLP-1 supplement-review guide

GLP-1 and creatine: interaction, muscle, kidney, and scale questions

Review creatine during semaglutide, tirzepatide, Wegovy, Ozempic, Zepbound, or Mounjaro care with evidence limits, kidney and hydration context, lab interpretation, and supplement-quality checks.

Educational guideUpdated August 6, 2026

A safer GLP-1 and creatine review

Identify the exact GLP-1 or GIP/GLP-1 product, route, current plan, recent changes, prescriber, and dispensing pharmacy.

Define the creatine goal: resistance-training performance, strength, lean-mass concern, recovery, or a social-media claim about preventing “Ozempic muscle loss.”

Review kidney history, baseline and recent labs, hydration, urine changes, nausea, vomiting, diarrhea, low intake, diabetes medicines, and other supplements.

Separate true fat or lean-tissue change from creatine-related water-weight change and possible changes in serum creatinine interpretation.

Choose clinician-directed nutrition and exercise follow-up rather than a supplement stack, copied dose plan, or unverified compounded GLP-1 seller.

Direct answer

Current Wegovy and Zepbound labels do not identify creatine as a named contraindication, but that does not prove every creatine product is appropriate with every GLP-1 plan. There is not established clinical evidence that creatine prevents lean-mass loss specifically during semaglutide or tirzepatide treatment. Before combining them, ask the prescribing clinician to review the exact GLP-1 product and route, kidney history and laboratory results, nausea, vomiting or diarrhea, hydration and urine changes, diabetes medicines, exercise and nutrition goals, and every ingredient in the supplement. Do not stop, delay, restart, or change a GLP-1 medicine—or begin a creatine loading or supplement protocol—from a generic online answer.

Interaction evidence

No named label contraindication is not the same as a universal green light

Current manufacturer labeling for Wegovy and Zepbound does not list creatine as a named contraindication or establish a creatine-specific drug interaction. However, “GLP-1” covers different active ingredients, indications, routes, presentations, and patient histories, while a creatine product may be single-ingredient creatine monohydrate or a multi-ingredient pre-workout. Current GLP-1 labels also warn about gastrointestinal reactions and acute kidney injury due to volume depletion. The practical review therefore centers on the exact products, fluid-loss symptoms, kidney context, glucose medicines, exercise plan, and the complete supplement label rather than a yes-or-no interaction checker.

Wegovy currently includes injection and tablet presentations; an answer written only for a weekly injection should not be applied automatically to every semaglutide route.
Zepbound, Mounjaro, branded semaglutide products, and patient-specific compounded semaglutide or tirzepatide preparations have product-specific instructions and should not be treated as interchangeable.
A patient-specific compounded GLP-1 preparation is not an FDA-approved finished drug product and may differ in concentration, presentation, inactive ingredients, supplies, labeling, and storage.

Lean-mass evidence

Creatine has exercise research, but GLP-1-specific preservation evidence is not established

Recent systematic reviews of incretin-based treatment found that significant weight loss can include a decrease in measured lean mass, with the amount and proportion varying by medicine, population, measurement method, comparator, and study. A 2026 meta-analysis found that the proportion of weight lost as lean mass was broadly comparable between incretin treatment and lifestyle-only weight loss, while lifestyle programs that included resistance training had a more favorable profile. A current randomized trial is studying resistance exercise and protein during semaglutide or tirzepatide treatment, but its publication is a protocol, not a result. None of these sources establishes that creatine prevents GLP-1-related lean-mass loss.

Do not turn general creatine-and-resistance-training research into a promise that creatine prevents sarcopenia, offsets rapid weight loss, or guarantees muscle retention during GLP-1 care.
Ask how strength, physical function, food intake, protein adequacy, resistance activity, symptoms, and body-composition questions will be followed over time.
Older age, frailty, prior bariatric surgery, low intake, eating-disorder history, kidney disease, injury, or unexplained weakness can make individualized nutrition, exercise, or in-person assessment more important than adding a supplement.

Scale and laboratory context

Water weight and serum creatinine can complicate progress checks

NIH’s Office of Dietary Supplements notes that creatine commonly causes some weight gain through water retention and can cause gastrointestinal symptoms in some users. A 2026 systematic review of randomized trials found a small average increase in serum creatinine without a statistically significant difference in estimated glomerular filtration rate or urea, while also calling for longer-term trials. That population-level finding does not diagnose an individual laboratory change or establish safety for a person with kidney disease, dehydration, severe vomiting or diarrhea, multiple medicines, or an unclear supplement product.

Tell the clinician and laboratory team about creatine use before interpreting serum creatinine, estimated kidney function, a sudden scale change, or a body-composition trend.
Do not assume a higher creatinine result is harmless, and do not assume every short-term scale increase is new fat or muscle; the clinical context and trend matter.
Persistent vomiting or diarrhea, inability to keep fluids down, reduced urination, fainting, confusion, severe weakness, severe abdominal pain, blood in urine, or another rapidly worsening symptom needs prompt medical guidance rather than supplement troubleshooting.

Product and symptom review

Check the full supplement label and overlapping GI or glucose concerns

A product labeled “creatine” may also contain caffeine, stimulants, sweeteners, electrolytes, amino acids, herbs, vitamins, or proprietary blends. Nausea, diarrhea, cramping, low intake, dizziness, sleep disruption, palpitations, or glucose changes can be harder to interpret when several products begin together. Current Wegovy and tirzepatide labels also contain product-specific warnings about low blood sugar when used with insulin or insulin secretagogues. One responsible clinician or pharmacist should reconcile the full list before a new supplement is added.

Share insulin, sulfonylureas, metformin, SGLT2 inhibitors, diuretics, blood-pressure medicines, NSAIDs, kidney-related medicines, caffeine, pre-workouts, protein powders, electrolytes, and every other supplement.
Avoid proprietary blends, stimulant-heavy “GLP-1 muscle saver” products, counterfeit testing seals, hidden ingredient amounts, disease-treatment claims, and bundles that require several simultaneous changes.
Introduce no self-directed GLP-1 dose change, restart, extra injection, product switch, or compounded-vial conversion to accommodate a workout or supplement routine.

Care plan

Start with the goal, baseline, and follow-up—not a loading chart

A useful plan defines why creatine is being considered and how the answer will be measured. Strength, walking tolerance, resistance-training consistency, dietary intake, hydration, weight trend, waist trend, symptoms, and clinician-selected labs may answer different questions. The plan should also explain who reviews side effects, what happens during illness or poor intake, and when local primary care, nutrition, kidney, sports-medicine, or physical-therapy input is more appropriate than another telehealth add-on.

Ask whether the goal is better served first by an appropriate resistance program, adequate nutrition, symptom control, medication review, physical therapy, or evaluation of anemia, thyroid disease, sleep apnea, injury, or another cause of weakness.
Use the exact GLP-1 prescription label and a complete supplement label; do not use this page as a creatine dose, loading, mixing, or injection guide.
A credible clinic does not guarantee muscle preservation, sell research-use GLP-1 products for human use, or imply that a compounded preparation or supplement is an FDA-approved finished drug.

Patient safety checklist

Questions to ask before using creatine during GLP-1 treatment

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Which exact medicine, active ingredient, brand or compounded status, route, presentation, prescription label, pharmacy, and recent treatment change apply?

✓

Why am I considering creatine: strength, training performance, lean-mass concern, recovery, scale changes, fatigue, or an online “muscle saver” claim?

✓

What are my baseline strength, function, food intake, protein pattern, activity, weight trend, symptoms, kidney history, and relevant laboratory results?

✓

Have nausea, vomiting, diarrhea, constipation, low intake, dizziness, dehydration, reduced urination, or illness affected the current plan?

✓

Do insulin, sulfonylureas, metformin, SGLT2 inhibitors, diuretics, blood-pressure medicines, NSAIDs, kidney-related medicines, or other prescriptions change the review?

✓

Is the supplement single-ingredient creatine monohydrate, or does it also contain caffeine, stimulants, electrolytes, herbs, amino acids, sweeteners, or a proprietary blend?

✓

How will the clinician interpret water-weight changes, serum creatinine, estimated kidney function, and body-composition measurements after creatine begins?

✓

Who should be contacted for persistent GI symptoms, low intake, glucose concerns, abnormal labs, severe weakness, reduced urination, or another change before the next treatment decision?

FAQs

Short answers for patients

Can you take creatine with a GLP-1 medicine?

Some patients may be able to after individualized review, but there is no universal answer. The clinician should confirm the exact GLP-1 and creatine products, kidney history and labs, hydration and GI symptoms, glucose medicines, exercise goal, and all other ingredients or supplements before deciding whether the combination fits.

Does creatine interact with semaglutide or tirzepatide?

Current Wegovy and Zepbound labels do not name creatine as a specific contraindication, but that does not establish safety for every patient or product. GI fluid loss, kidney context, laboratory interpretation, glucose medicines, other ingredients, and compounded-versus-branded identity can still matter.

Does creatine prevent muscle loss on Ozempic, Wegovy, Zepbound, or Mounjaro?

That has not been established. Creatine has human research in resistance-training settings, but current incretin body-composition reviews and the ongoing resistance-exercise-and-protein trial do not show that creatine specifically prevents lean-mass loss during these treatments. Avoid guaranteed “GLP-1 muscle saver” claims.

Can creatine make the scale go up during GLP-1 treatment?

Creatine can increase body water and short-term scale weight, so one increase does not by itself show new fat or muscle. Review timing, symptoms, hydration, weight trend, strength or function, and the measurement method rather than changing GLP-1 treatment from one reading.

Can creatine change kidney blood-test results?

Creatine can raise serum creatinine in some people and complicate interpretation. A 2026 randomized-trial meta-analysis did not find a significant average difference in estimated filtration rate or urea, but that does not rule out kidney disease or make every individual change harmless. Disclose creatine and let the clinician interpret the full history and laboratory pattern.

Should I stop creatine or my GLP-1 during vomiting or diarrhea?

Do not make a generic stop, restart, or dose-change decision from this page. Contact the responsible clinician promptly because fluid loss, reduced intake, kidney risk, glucose medicines, symptom severity, and the exact products determine the response. Inability to keep fluids down, reduced urination, fainting, confusion, severe weakness, or severe abdominal pain can require urgent assessment.

Is compounded semaglutide or tirzepatide different for this decision?

Yes. A patient-specific compounded preparation is not an FDA-approved finished drug product and can differ in concentration, inactive ingredients, presentation, supplies, labeling, and storage. Confirm the prescriber, licensed dispensing pharmacy, patient label, and follow-up pathway before adding supplements or changing treatment.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Current WEGOVY prescribing information — injection and tablet presentations DailyMed: Current ZEPBOUND prescribing information NIH Office of Dietary Supplements: Dietary Supplements for Exercise and Athletic Performance PubMed: Lean mass changes with incretin therapy versus lifestyle intervention — 2026 systematic review and meta-analysis PubMed: GLP-1 receptor agonists and lean body mass — 2026 systematic review and meta-analysis PubMed: LEAN-PREP resistance exercise and protein trial protocol during semaglutide or tirzepatide therapy PubMed: Creatine supplementation and kidney function — 2026 systematic review and meta-analysis FDA: Compounding and the FDA — Questions and Answers Peptide12: Compounded semaglutide injection Peptide12: Compounded tirzepatide injection Peptide12: GLP-1 protein-intake questions Peptide12: GLP-1 muscle-loss guide Peptide12: Nutrition, protein, and exercise questions Peptide12: Hydration and electrolyte questions Peptide12: Medication and supplement review Peptide12: Pharmacy quality checklist Peptide12: How online peptide therapy works